分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Two Hippo signaling modules orchestrate liver size and tumorigenesis

Sixian Qi, Zhenxing Zhong, Yuwen Zhu, Yebin Wang, Mingyue Ma, Yu Wang, Xincheng Liu, Ruxin Jin, Zhihan Jiao, Rui Zhu, Zhao Sha, Kyvan Dang, Ying Liu, Dae-Sik Lim, Junhao Mao, Lei Zhang, Fa-Xing Yu

Journal:EMBO JOURNAL

IF:11.4

DOI:10.15252/embj.2022112126

PMID:36919851

Published:2023-03-15

research field:分子生物学细胞生物学癌症生物学遗传学

Abstract

The Hippo pathway is a central regulator of organ size and tumorigenesis and is commonly depicted as a kinase cascade, with an increasing number of regulatory and adaptor proteins linked to its regulation over recent years. Here, we propose that two Hippo signaling modules, MST1/2–SAV1–WWC1-3 (HPO1) and MAP4K1-7–NF2 (HPO2), together regulate the activity of LATS1/2 kinases and YAP/TAZ transcriptional co-activators. In mouse livers, the genetic inactivation of either HPO1 or HPO2 module results in partial activation of YAP/TAZ, bile duct hyperplasia, and hepatocellular carcinoma (HCC). On the contrary, inactivation of both HPO1 and HPO2 modules results in full activation of YAP/TAZ, rapid development of intrahepatic cholangiocarcinoma (iCCA), and early lethality. Interestingly, HPO1 has a predominant role in regulating organ size. HPO1 inactivation causes a homogenous YAP/TAZ activation and cell proliferation across the whole liver, resulting in a proportional and rapid increase in liver size. Thus, this study has reconstructed the order of the Hippo signaling network and suggests that LATS1/2 and YAP/TAZ activities are finetuned by HPO1 and HPO2 modules to cause different cell fates, organ size changes, and tumorigenesis trajectories.

本文使用的Yeasen产品

购物车
客服
转染试用